Oral Cocktail of Polyphenols, NAD+ Precursor and Captopril Shields Mice From Lethal Radiation
A fully oral blend of pterostilbene, silybin, nicotinamide riboside and captopril helped 90% of mice survive lethal X-rays while sparing tumor radiotherapy effects.
Zusammenfassung
Researchers tested an all-oral combination of pterostilbene cocrystals, silybin-phosphatidylcholine, nicotinamide riboside (an NAD+ precursor) and captopril as a countermeasure against high-dose radiation. In mice given a lethal dose of X-rays (LD50/30), the formulation produced long-term survival in 90% of animals. It reduced damage to blood-forming, intestinal and neuromotor systems, boosted DNA repair, lowered oxidative stress, preserved NAD+ levels and activated autophagy. Importantly, it did not blunt radiotherapy against tumors: radiation-induced regression was preserved in triple-negative breast cancer models, and glioblastoma became more radiosensitive. These are preclinical findings from an abstract only, and the authors have commercial interests, so human relevance remains unproven.
Detaillierte Zusammenfassung
Ionizing radiation can cause severe damage to multiple organs, whether from accidents, occupational exposure, or cancer radiotherapy. No broadly effective oral countermeasure has been validated, and a major concern with radioprotectors is that they might also shield tumors.
This study evaluated a fully oral, multi-component formulation: pterostilbene cocrystals and silybin-phosphatidylcholine (bioavailable polyphenol derivatives), nicotinamide riboside (an NAD+ precursor), and captopril, an ACE inhibitor with known radiomitigative activity that the authors report synergizes with the polyphenols. The team tested it in mice exposed to a lethal X-ray dose (LD50/30), in intestinal epithelial cells, and in tumor models.
The combination yielded long-term survival in 90% of irradiated mice. It mitigated hematopoietic, intestinal and neuromotor injury, enhanced DNA repair, suppressed oxidative stress, preserved NAD+ homeostasis and activated autophagy. In intestinal cells it reduced apoptosis, inflammatory signaling and mitochondrial dysfunction, apparently via coordinated modulation of Nrf2, NF-κB and sirtuin-regulated pathways. In triple-negative breast cancer models, radiation-induced tumor regression was preserved. In glioblastoma, a typically radioresistant cancer, radiosensitivity was significantly enhanced through sustained oxidative stress, reduced PARP1 expression, and inhibition of HIF-1α and VEGF signaling.
If replicated, this suggests a practical, orally deployable approach that protects normal tissue while preserving or augmenting radiotherapy efficacy, with potential uses in radiotherapy support and radiation emergencies.
Caveats: only the abstract was available, so doses, group sizes, controls and statistics could not be assessed. Results are preclinical, and the formulation's components were not individually detailed here. Several authors hold stock in or consult for companies involved, so independent replication and human trials are needed.
Wichtigste Erkenntnisse
- The oral formulation produced long-term survival in 90% of mice given a lethal (LD50/30) X-ray dose.
- It mitigated hematopoietic, intestinal and neuromotor radiation injury while enhancing DNA repair and activating autophagy.
- In intestinal cells it cut apoptosis, inflammation and mitochondrial dysfunction via Nrf2, NF-κB and sirtuin pathways.
- Radiation-induced regression of triple-negative breast cancer models was preserved despite normal-tissue protection.
- Glioblastoma models became significantly more radiosensitive, with reduced PARP1 and inhibited HIF-1α and VEGF signaling.
Methodik
Preclinical study using lethal-dose (LD50/30) X-ray exposure in mice, mechanistic work in intestinal epithelial cells, and tumor models of triple-negative breast cancer and glioblastoma. Endpoints included survival, tissue injury, DNA repair, oxidative stress, NAD+ levels, autophagy and tumor response. Details of design, dosing and sample sizes were not available in the abstract.
Studienlimitierungen
Evidence comes from an abstract describing animal and cell models; effective human doses, safety, drug interactions (e.g., captopril with other agents) and the contribution of each component are unknown. Authors disclose financial ties to companies developing the formulation, and independent replication is lacking.
Hat dir diese Zusammenfassung gefallen?
Erhalte die neueste Longevity-Forschung jede Woche in deinen Posteingang.
E-Mail-Adresse zum Abonnieren eingeben: